¼¼°èÀÇ Æó±â´É °Ë»ç ½Ã½ºÅÛ ½ÃÀåÀº 2024³â 29¾ï ´Þ·¯¿¡ ´ÞÇß°í, 2025³âºÎÅÍ 2034³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 6.6%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.
ÀÌ ±Þ¼ºÀåÀÇ ¹è°æÀº Áø´Ü ±â¼úÀÇ ²÷ÀÓ¾ø´Â Áøº¸, Àα¸ °í·ÉÈ, Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, °Ç° °ü¸® ÀÎÇÁ¶ó °³¼± µîÀÌ ÀÖ½À´Ï´Ù. È£Èí±â ÁúȯÀÌ ¸¸¿¬ÇÏ´Â µ¿¾È °Ç° °ü¸® Á¦°ø¾÷ü´Â Á¶±â Áø´Ü°ú È¿À²ÀûÀÎ Áúº´ °ü¸®¸¦ ¼±È£Çϰí ÀÖÀ¸¸ç, ÀÌ´Â °í±Þ Æó±â´É °Ë»ç ½Ã½ºÅÛ ¼ö¿ä¸¦ Å©°Ô ¹Ð°í ÀÖ½À´Ï´Ù. ¼ÒÇüÀÇ °íÁ¤¹Ð ±â±âÀÇ Çõ½Å¿¡ ÀÇÇØ ´Ù¾çÇÑ ÇコÄɾî ȯ°æ¿¡ ÀÖ¾î¼ Æó±â´É Æò°¡°¡ º¸´Ù Ä£¼÷ÇØÁö°í ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î Áø´Ü µµ±¸·ÎÀÇ ÀüȯÀÌ ¾÷°è¸¦ Çü¼ºÇÏ¿© ÀÓ»ó ¹× °¡Á¤ ȯ°æ¿¡¼ÀÇ Ã¤¿ëÀ» ÃËÁøÇÕ´Ï´Ù.
½ÃÀåÀÇ ¼ºÀåÀº ÀÇ·á ±â¼ú°ú µðÁöÅÐ ÅëÇÕ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ·Î Æó Æò°¡ÀÇ È¿À²¼º°ú ½Å·Ú¼ºÀÌ Çâ»óµÇ°í ÀÖ´Ù´Â Á¡À» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀΠȣÈí ¸ð´ÏÅ͸µ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¦Á¶¾÷ü¿Í ±â´É¼º°ú Á¤È®¼ºÀÌ Çâ»óµÈ Àåºñ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ ½ÃÀÛÀº È£Èí±â Áø´Ü¿¡ º¯È¸¦ °¡Á®¿À°í ȯÀÚ¿Í ÀÇ·á Àü¹®°¡ ¸ðµÎ¿¡°Ô ´õ Æí¸®ÇÕ´Ï´Ù. °³ÀÎÈµÈ ÀǷḦ À§ÇÑ ¾÷°èÀÇ ¿òÁ÷ÀÓ¿¡ µû¶ó Æó±â´É °Ë»ç ½Ã½ºÅÛÀº º¸´Ù Á¤È®Çϰí ȯÀÚ¿¡°Ô Æ¯ÈµÈ Áö½ÄÀ» Á¦°øÇϵµ·Ï ÁøÈÇϰí ÀÖ½À´Ï´Ù. ¿¹¹æÀÇ·á¿¡ ´ëÇÑ ´ëó¿Í ±¤¹üÀ§ÇÑ ½ºÅ©¸®´× ÇÁ·Î±×·¥ÀÌ º¸±ÞÀ» °¡¼Ó½Ã۰í ÀÖ¾î ÇâÈÄ ¸î ³â°£ÀÇ ²ÙÁØÇÑ È®´ë¸¦ È®½ÇÈ÷ Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 29¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 54¾ï ´Þ·¯ |
CAGR | 6.6% |
ÈÞ´ë¿ë ¹× ¼ÒÇü Áø´Ü Àåºñ´Â »ç¿ëÀÇ ¿ëÀ̼º°ú ´Ù¾çÇÑ °Ç° °ü¸® ȯ°æ¿¡¼ Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ Å« ¼ö¿ä°¡ ¹ß»ýÇÕ´Ï´Ù. ÇÚµåÇïµå ¼¼ºÐȰ¡ ½ÃÀåÀ» ¼±µµÇϰí 2024³â¿¡´Â 17¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ë È¿À²ÀûÀÎ Àåºñ´Â ƯÈ÷ ÇÕ¸®ÀûÀÎ °¡°ÝÀÌÁö¸¸ Á¤È®ÇÑ È£Èí Æò°¡°¡ ÇÊ¿äÇÑ ¼Ò±Ô¸ð ÀÇ·á ½Ã¼³¿¡¼´Â ½ÇÇè½Ç ±â¹Ý ´ëÇü Àåºñº¸´Ù ¼±È£µË´Ï´Ù. ½Ç½Ã°£ °Ë»ç¿¡ À¯¿¬ÇÏ°Ô ´ëÀÀÇÒ ¼ö Àֱ⠶§¹®¿¡ º¹¼öÀÇ ÀÇ·á ¿ëµµ·Î ä¿ëÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü°¡ Àåºñ ¼º´ÉÀ» °³¼±ÇÏ°í »ç¿ëÀÚ ÆíÀǼºÀ» ³ôÀÌ¸é¼ ¾÷°è´Â µðÁöÅÐ ¿¬°á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â´ÉÀ¸·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. Á¤È®ÇÏ°í »ç¿ëÇϱ⠽¬¿î Æó±â´É °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí Çö´ë °Ç° °ü¸® ½Ã½ºÅÛ¿¡¼ Æó±â´É °Ë»ç ¼Ö·ç¼ÇÀÇ Áß¿äÇÑ ¿ªÇÒÀ» °ÈÇϰí ÀÖ½À´Ï´Ù.
¸¸¼º È£Èí±â ÁúȯÀº ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀÌ¸ç ¸¸¼º ÁúȯÀÌ ¼ö¿äÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¸¸¼º Æó¼â¼º ÆóÁúȯ(COPD) ºÎ¹®Àº 2024³â 39.8% ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ȯ°æ¿À¿°¹°Áú°ú ¶óÀÌÇÁ½ºÅ¸ÀÏ ¿äÀο¡ ÀÇÇÑ ÆóÁúȯÀÇ ÀÌȯÀ²ÀÇ »ó½ÂÀ¸·Î Æó±â´É °Ë»ç´Â ÀÏ»óÀûÀÎ ÇコÄɾ ºü¶ß¸± ¼ö ¾ø°Ô µÇ¾ú½À´Ï´Ù. ¸¸¼º È£Èí±â ÁúȯÀÌ ¸¸¿¬ÇÔ¿¡ µû¶ó °Ç° °ü¸® Á¦°ø¾÷ü´Â Á¶±â °³ÀÔÀ» ÃËÁøÇϱâ À§ÇØ °í±Þ Áø´Ü Àåºñ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Áúº´ÀÇ ÁøÇàÀ» ´ÊÃß±â À§Çؼ´Â Á¶±â ¹ß°ßÀÌ Áß¿äÇϱ⠶§¹®¿¡ Á¤¹ÐÇÑ Æó±â´É Æò°¡¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. °Ë»ç ±â¼úÀÇ ¹ßÀüÀº È¿À²¼ºÀ» Çâ»ó½ÃŰ°í ´õ ³ªÀº ¸ð´ÏÅ͸µ ¹× Áúº´ °ü¸® ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÇコÄɾî ÀÎÇÁ¶óÀÇ È®´ë´Â ÃÖ÷´Ü Æó±â´É °Ë»ç Àåºñ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±ÇÏ°í ½ÃÀå ÀüüÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
¹Ì±¹ÀÇ Æó±â´É °Ë»ç ½Ã½ºÅÛ ½ÃÀåÀº 2024³â 13¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç 2034³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 5.4%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÇ·á ±â¼úÀÇ ¼¼°èÀûÀÎ ¼±µÎÁÖÀÚÀÎ ¹Ì±¹Àº °íÁ¤¹Ð Áø´Ü µµ±¸¸¦ ÀÇ·á±â°ü¿¡ Áö¼ÓÀûÀ¸·Î ÅëÇÕÇÏ¿© Æó±â´É Æò°¡ÀÇ Á¤È®¼º°ú È¿À²¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. µðÁöÅÐ ±â±â¿Í ¹«¼± ´ëÀÀ ±â±âÀÇ º¸±Þ¿¡ ÀÇÇØ Æó±â´É °Ë»ç°¡ ´õ¿í ÇÕ¸®ÈµÇ¾î ½ÃÀå Àüü ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ±â¼ú Çõ½Å¿¡ ´ëÇÑ ÅõÀÚ°¡ Ȱ¹ßÇØÁö°í Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¹Ì±¹ ½ÃÀåÀº ÇâÈÄ 10³â°£ ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀ» ÀÌ·ê ¼ö ÀÖ½À´Ï´Ù.
The Global Pulmonary Function Testing Systems Market reached USD 2.9 billion in 2024 and is on track to expand at a CAGR of 6.6% between 2025 and 2034. This rapid growth is fueled by continuous advancements in diagnostic technologies, an aging population, increased awareness of early disease detection, and improved healthcare infrastructure. With respiratory diseases becoming more prevalent, healthcare providers are prioritizing early diagnosis and efficient disease management, which is significantly boosting the demand for advanced pulmonary function testing systems. Innovations in compact, high-precision devices are making pulmonary assessments more accessible across various healthcare settings. The shift toward cost-effective and user-friendly diagnostic tools is shaping the industry, driving greater adoption in clinical and home-based environments.
Market growth is further supported by ongoing investments in medical technology and digital integration, enhancing the efficiency and reliability of pulmonary assessments. The increasing need for continuous respiratory monitoring is pushing manufacturers to develop devices with improved functionality and accuracy. The rise of wearable and remote monitoring solutions is transforming respiratory diagnostics, making them more convenient for both patients and healthcare professionals. As the industry moves toward personalized medicine, pulmonary function testing systems are evolving to provide more precise and patient-specific insights. Preventive care initiatives and widespread screening programs are accelerating adoption, ensuring steady expansion in the coming years.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $2.9 Billion |
Forecast Value | $5.4 Billion |
CAGR | 6.6% |
Portable and compact diagnostic devices are experiencing significant demand due to their ease of use and ability to provide precise results in various healthcare environments. The handheld segment led the market, generating USD 1.7 billion in revenue in 2024. These cost-efficient devices are favored over larger, laboratory-based equipment, particularly by smaller healthcare facilities that require affordable yet accurate respiratory assessments. Their flexibility in delivering real-time testing has led to increased adoption across multiple medical applications. As manufacturers refine device performance and enhance user convenience, the industry is shifting toward digital connectivity and remote monitoring capabilities. The rising demand for accurate and accessible pulmonary function testing solutions is driving innovation, reinforcing their essential role in modern healthcare systems.
Chronic respiratory conditions are a major factor driving market expansion, with chronic diseases accounting for a substantial portion of demand. The chronic obstructive pulmonary disease (COPD) segment held a 39.8% market share in 2024. The rising incidence of pulmonary disorders due to environmental pollutants and lifestyle factors has made pulmonary function testing a crucial part of routine healthcare. As chronic respiratory diseases become more prevalent, healthcare providers are investing in advanced diagnostic equipment to facilitate early intervention. The importance of early detection in slowing disease progression is increasing demand for precise pulmonary assessments. Advancements in testing technology are improving efficiency, thus offering better monitoring and disease management solutions. Expanding healthcare infrastructure is also improving access to state-of-the-art pulmonary function testing devices, driving overall market growth.
The US pulmonary function testing systems market was valued at USD 1.3 billion in 2024 and is projected to grow at a CAGR of 5.4% through 2034. As a global leader in medical technology, the US continues to integrate high-precision diagnostic tools into healthcare institutions, improving accuracy and efficiency in pulmonary assessments. The widespread adoption of digital and wireless-enabled devices is further streamlining pulmonary function testing, increasing overall market demand. With strong investments in healthcare innovation and a rising focus on early disease detection, the US market is well-positioned for consistent growth over the next decade.